News | August 05, 2024
Divis Laboratories reports Q1 FY25 consolidated PAT at Rs. 430 Cr
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
Subscribe To Our Newsletter & Stay Updated
